Cellgenic launches regulated commercial operations in Argentina, creating a platform for biologics distribution, physician education, and regional expansion.
BOCA RATON, FL — April 26, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”), through its wholly owned subsidiary Global Stem Cells Group and its commercial division Cellgenic, today announced a major expansion of its Latin American operations with the establishment of Cellgenic’s commercial platform in Argentina.
The expansion follows the completion of regulatory and operational milestones that allow Cellgenic to commercialize qualifying biologic and regenerative medicine products through licensed medical practitioners in compliance with applicable Argentine regulations.
The Company believes this represents one of the most significant strategic initiatives in Cellgenic’s international growth strategy and positions Argentina to become one of its principal operating hubs for South America.
“Argentina represents a unique opportunity for Cellgenic,” said David Christensen, Chief Executive Officer of Regenerative Medical Technology Group. “The combination of scientific talent, established clinical infrastructure, and a supportive regulatory framework creates an environment where we believe we can significantly expand physician access to advanced regenerative medicine products while building a scalable commercial operation throughout the region.”
Unlike many markets where regulatory uncertainty has limited physician adoption of regenerative medicine products, Cellgenic’s operational platform is designed to provide physicians with compliant access to high-quality biologic products supported by education, technical resources, and commercial infrastructure.
As part of the expansion, Cellgenic expects to:
- Expand its commercial sales organization throughout Argentina;
- Conduct physician education conferences, workshops and certification programs in collaboration with ISSCA;
- Develop new clinical collaborations and scientific case studies;
- Increase physician adoption of regenerative medicine products;
- Expand distribution capabilities throughout Argentina and neighboring Latin American markets; and
- Establish Argentina as one of Cellgenic’s primary regional centers for future growth.
The Company believes that regulatory compliance, physician education, and commercial infrastructure are critical components required for widespread adoption of regenerative medicine technologies. By integrating these elements into a unified operating platform, Cellgenic seeks to accelerate market development while supporting physicians practicing within applicable regulatory guidelines.
This initiative also strengthens the strategic relationship between Cellgenic’s commercial organization and ISSCA’s physician education platform. Through conferences, advanced certification programs, and hands-on training events, the Company expects to significantly increase physician engagement while supporting continued adoption of regenerative medicine technologies.
The Argentina expansion aligns with RMTG’s broader strategy of building an integrated global regenerative medicine ecosystem that combines physician education, biologics commercialization, laboratory capabilities, and international distribution. The Company currently operates across more than 30 countries and continues expanding its commercial footprint through strategic regional hubs.
“We are not simply entering another country,” added Christensen. “We are establishing the infrastructure necessary to support long-term physician education, commercialization, scientific collaboration, and continued expansion throughout Latin America. We believe Argentina will become an important cornerstone of Cellgenic’s international growth strategy for years to come.”
About Cellgenic
Cellgenic, a division of Global Stem Cells Group and Regenerative Medical Technology Group (OTC: RMTG), develops and commercializes regenerative medicine technologies, biologics, cell therapy products, exosomes, peptides, and related medical solutions for physicians and clinics worldwide.
About Regenerative Medical Technology Group
Regenerative Medical Technology Group, Inc. (OTC: RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated commercial expansion, future physician adoption, expected market opportunities, operational growth, revenue potential, geographic expansion, and other statements that are not historical facts. Actual results may differ materially due to various risks and uncertainties, including regulatory developments, market acceptance, operational execution, competitive conditions, economic factors, and other risks detailed in the Company’s filings with OTC Markets and applicable regulatory authorities.
